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Aim To determine whether microRNA (miR)-124 enhances 
the response to radiotherapy in human epidermal growth 
factor receptor 2 (HER2)-positive breast cancer cells by tar-
geting signal transducer and activator of transcription 3 
(Stat3).
Methods miR-29b expression was measured in 80 pairs of 
breast tumor samples and adjacent normal tissues collect-
ed between January 2013 and July 2014. Activity changes 
of 50 canonical signaling pathways upon miR-124 overex-
pression were determined using Cignal Signal Transduc-
tion Reporter Array. Target gene of miR-124 was deter-
mined using Targetscan and validated by Western blotting 
and dual-luciferase assay. Cell death rate was assessed by 
propidium iodide (PI)/Annexin V staining followed by flow 
cytometry analysis. Stat3 and miR-124 expression was fur-
ther measured in 10 relapsed (non-responder) and 10 re-
currence-free HER2-positive breast cancer patients.
Results MiR-124 expression was down-regulated in HER2 
positive breast cancers compared with normal tissues, and 
was negatively associated with tumor size. MiR-124 over-
expression in HER2 positive breast cancer cell line SKBR3 
significantly reduced the activity of Stat3 signaling path-
way compared with control transfection (P < 0.001). Bio-
informatic prediction and function assay suggested that 
miR-124 directly targeted Stat3, which is a key regulator of 
HER2 expression. MiR-124 overexpression down-regulated 
Stat3 and potently enhanced cell death upon irradiation. 
Consistently, chemical inhibitor of Stat3 also sensitized 
HER2-positive breast cancer cells to irradiation. Moreover, 
increased Stat3 expression and reduced miR-124 expres-
sion were associated with a poor response to radiotherapy 
in HER2-positive breast cancers.
Conclusions Weak miR-124 expression might enhance 
Stat3 expression and radiotherapy resistance in HER2-pos-
itive breast cancer cells.
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Breast cancer is the most common female malignancy 
worldwide, with nearly 1.7 million cases diagnosed each 
year (1). The etiology of this malignant disease is complex. 
Based on its characteristics, treatment regimens, and clini-
cal outcomes, breast cancer is commonly categorized into 
5 subtypes, including luminal A, luminal B, basal-like, HER2-
positive, and normal-like (2). Of note, HER2-positive breast 
cancer, which accounts for about 25% of all cancer cases, is 
associated with a poor prognosis and a high recurrence rate 
(1,3). Accordingly, understanding the molecular mechanisms 
underlying the etiology of different breast cancer subtypes is 
critical to the development of novel therapies and improve-
ment of clinical outcomes of breast cancer patients.
MicroRNAs (miRNAs) are a 21-25 long class of small non-
protein coding RNA, which are critical in regulating gene 
expression by degrading the target mRNAs and/or inhibit-
ing translation (4,5). By targeting different genes with vari-
ous oncogene or tumor-suppressor functions, miRNAs are 
playing a wide range of roles in regulating proliferation, 
apoptosis, metastasis, and resistance to various therapies. 
Consistent with their critical roles in tumorigenesis, single-
nucleotide variants and copy-number changes in miRNA 
genes are frequently observed in various cancers (5-8). 
Abnormal transcription and defects in miRNA biogenesis 
may also influence the production of cancer-related miR-
NAs (9). Moreover, as miRNAs could be selectively pack-
aged into exosomes and differentially secreted, circulating 
miRNAs have therefore emerged as a sensitive marker for 
early cancer detection.
Accumulating evidence has supported the role of miR-124 
as an important tumor suppressor, and reduced miR-124 
expression or its lack was reported in several types of hu-
man cancers. Notably, it has been reported that poor ex-
pression of microRNA-124 is a prognostic biomarker of 
breast cancer patients, while miR-124 suppresses multiple 
steps of breast cancer metastasis by targeting a cohort of 
pro-metastatic genes (10-14) However, the role of miR-124 
in HER2-positive breast cancer remains largely unknown. 
Therefore, the aim of this study was to investigate the as-
sociation between miR-124 expression and different path-
ological and clinical characteristics of patients with HER2-
positive breast cancer. We also identified Stat3 as the major 
target of miR-124. It has been shown that STAT3-survivin 
signaling mediated a poor response to radiotherapy in 
HER2-positive breast cancers (15). We thus hypothesized 
that weakly expressed miR-124 might enhance Stat3 ex-
pression and activity, contributing to radiotherapy re-
sistance in these cells.
Materials and Methods
tumor tissues and cell culture
The study design was revised and approved by the In-
stitutional Ethics Committee of the First Affiliated Hos-
pital of Nanchang University and informed consent was 
obtained from each patient. Pathological and clinical 
information on these patients is shown in Table 1. Only 
patients who did not receive any therapy before recruit-
ment to this research were included in the study. Be-
tween January 2013 and July 2014, 80 tumor samples and 
matching adjacent normal tissues from the same patients 
collected in the First Affiliated Hospital of Nanchang Uni-
versity. Samples were stored in RNAlater solution (Ambi-
on, Chelmsford, MA, USA), confirmed by pathologists and 
then stored at -80°C until total RNA extraction. For radia-
table 1. expression of microrna-124 and clinicopathological 







tumor 80 1.00 ±0.67 0.0016†
normal 80 2.65±0.91
age (years)
<50 16 1.12±0.56 0.36
>50 64 0.95±0.51
tumor size (cm)
<5 33 0.81±0.59 0.033†
>5 47 1.15±0.52
stage
I 11 0.87±0.66 0.061
II-IV 69 1.02±0.59
histology
infiltrating duct 51 0.98±0.65 0.58
infiltrating lobular 29 1.06±0.61
lymph node metastasis
absent 25 1.09±0.71 0.45
present 55 0.95±0.57
estrogen-receptor status
positive 52 0.95±0.55 0.67
negative 28 1.11±0.63
Progesterone receptor status
positive 39 1.03±0.55 0.58
negative 41 0.97±0.59
human epidermal growth factor receptor 2 status
positive 32 0.81±0.51 0.024†
negative 48 1.13±0.68
*data are presented as means ± standard deviation. Mean expression 
of all tumor samples was normalized to 1.00. 
†P < 0.05, t-test.
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tion therapy resistance analysis, tumor samples were ob-
tained from an independent cohort of 20 patients treated 
by curative surgery and adjuvant radiotherapy between 
February 2010 and July 2014. The human breast cancer 
cell lines SK-BR-3, T47D, and MCF7 obtained from the 
Shanghai Institute of Biological Sciences were cultured in 
DMEM (Thermo Fisher, Chelmsford, MA, USA) containing 
10% heat-inactivated fetal bovine serum (Thermo Fisher) 
and penicillin/streptomycin (Thermo Fisher), at 37°C with 
5% CO2.
rna extraction and real-time polymerase chain 
reaction (PCr)
We used Trizol reagent (Thermo Fisher) to extract total RNA 
from different tumor samples and cell lines. After extrac-
tion, RNA levels were analyzed for concentrations and pu-
rity using UV/Vis spectroscopy at 230, 260, and 280 nm. To-
tal RNA was used as the template for reverse transcription 
using the TaqMan Reverse Transcription Kit (Applied Bio-
systems, Carlsbad, CA, USA) with probes for miR-124 and 
U6 as the internal control. Quantitative PCR assays for each 
sample were run in triplicate using the TaqMan Real-Time 
PCR Kit (Applied Biosystems).
transfection of mir-124 duplex
MiR-124 duplex and the control oligo were obtained 
from Shanghai GenePharma Company (Shanghai, Chi-
na) and were transfected using Lipofectamine 2000 
(Thermo Fisher) at a final concentration of 50 nM. The 
sequences of the miRNA duplex were miR-124 sense: 5’- 
UAAGGCACGCGGUGAAUGCCA-3’; miR-124 antisense: 
3’-UAAUUCCGUGCGCCACUUACG-5’. Control sense: 5’-
AGUACUGCUUACGAUACGGTT-3’; Control antisense: 3’-
TTUCAUGACGAAUGCUAUGCC-5’.
Mirna target analysis and luciferase assay
Putative genes that are miR-124 targets were ana-
lyzed using TargetScan V7.1 (http://www.targetscan.
org/vert_71/). To generate the luciferase reporter vec-
tor, a 312 bp human Stat3 gene 3’-untranslated regions 
(3’-UTR) segment encompassing the predicted miR-124 
binding sites was PCR-amplified and subcloned into 
the pGL3 luciferase plasmid. The mutant construct was 
made with the QuikChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA). Dual luciferase activity as-
say was performed according to the instruction manual 
(Promega, Madison, WI, USA).
signal transduction reporter array
Activity changes of 50 canonical signaling pathways in re-
sponse to miR-124 overexpression were determined using 
Signal Transduction Reporter Array (Qiagen, Cambridge, 
MA, USA). Cells cultured in 6-well plate were transfected 
with miR-124 or scramble control for 36 h, and then plated 
on the Cignal Signal Transduction Reporter Array for trans-
fection with a mixture of a transcription factor responsive 
firefly luciferase reporter and a constitutively expressing 
Renilla construct in each well. The relative activity of each 
pathway was determined by luciferase/Renilla and normal-
ized by untreated controls.
Western blotting
10 μg proteins of each sample were separated on SDS-PAGE 
and subjected to immunoblotting using HER2 (1:1000, Cell 
signaling), p-Stat3 (1:1000, Abcam, Cambridge, MA, USA), 
Stat3 (1:1000, Abcam), Estrogen receptors (1:2000, Pro-
teintech, Rosemont, IL, USA), and Tubulin (1:5000, Sigma, 
St. Louis, MO, USA) antibodies. S3I-201 (100 μM; EMD Milli-
pore, Billerica, MA) were used to inhibit Stat3 activity.
irradiation and flow cytometry
Cells were seeded on 6-well plates and irradiated using a 
6-MV x-ray at a dose rate of 4 Gy/min (Varian Medical Sys-
tems, Palo Alto, CA, USA). For apoptosis assay using flow 
cytometry, cells were seeded in 6-well plates for 24 hours 
and transfected with different miRNA duplexes, or treated 
with S3I-201 or Dimethyl sulfoxide (DMSO) for 36 h. Fol-
lowing different treatment, cells were either were left un-
treated (0 Gy) or treated with 10 Gy of radiation (IR) for 
48 h. After this, cells were resuspended and stained with 
propidium iodide/Annexin V/ staining kit (Thermo Fisher), 
and the cell populations were analyzed by a FACSCalibur 
Flow Cytometer (BD, San Jose, CA, USA). The percentages 
of dead cells are presented as the percentage of PI-posi-
tive cells.
statistical analysis
All statistical analysis was also carried out using SPSS 17.0 
(SPSS Inc., Chicago, IL, USA) software. Data were expressed 
as the mean ± standard deviation of three biological rep-
licates. Kolmogorov-Smirnov test was used to determine 
the normality of distribution. t test or Mann-Whitney U 
test were to compare the two groups, and P-values 
<0.05 were considered significant.
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results
down-regulation of mir-124 in her2-positive breast 
cancers
MiR-124 expression was significantly down-regulated in tu-
mors compared with the matched normal tissues (Table 1, 
P = 0.002, paired t test). It was more likely to be down-regu-
lated in HER-2 positive cancers than in HER-2 negative can-
cers (Table 1, P = 0.02, t test) and was negatively associated 
with tumor size (Table 1, P = 0.03, t test). In contrast, it was 
not significantly associated with age, disease stage, histol-
ogy status, and lymph node metastasis, estrogen-receptor 
(ER) status, or progesterone receptor (PR) status (Table 1).
mir-124 overexpression in her2-positive breast cancer 
cells suppressed stat3 signaling
We then investigated the HER2 and ER status in several 
breast cancer cell lines. Western blotting results suggest-
ed that SKBR3 cell line was HER2-positive and ER-negative 
(HER2+/ER-), while T47D and MCF7 cells were largely HER2-
negative and ER-positive (HER2-/ER+) (Figure 1A). Interest-
ingly, qPCR miR-124 expression was significantly lower in 
SKBR3 cells than in T47D and MCF7 cells (Figure 1B), sug-
gesting a regulatory role of miR-124 inherently associated 
with HER2 expression.
To investigate the molecular mechanisms underlying 
miR-124 function in HER2-positive cells, we overexpressed 
miR-124 in SKBR3 cells. Transfection of miR-124 duplex in 
SKBR3 cells resulted in >20-fold increase in miR-124 ex-
pression compared with cells transfected with scramble 
control (Figure 1C). We then used a Cignal Signal Trans-
duction Reporter Array to investigate activity changes of 
50 canonical signaling pathways upon miR-124 overex-
pression. Based on pathway-specific transcription factor-
responsive luciferase reporters, this systematic approach 
allowed us to identify 10 signaling pathways that were sig-
nificantly suppressed and 4 signaling pathways that were 
Figure 1. Changes in signal transduction upon microrna-124 (mir-124) overexpression in human epidermal growth factor receptor 
2 (her-2)-positive cells. (A) sKbr3, t47d, and MCF7 breast cancer cells were analyzed by Western blotting for her2 and estrogen-
receptor expression. tubulin was used as a loading control. (B) Mir-124 expression of in sKbr3, t47d, and MCF7 cells by realtime 
polymerase chain reaction. (C) Mir-124 expression in sKbr3 cells following transfection with mir-124 duplex or scramble control. 
(D) significantly altered signaling pathways upon mir-124 overexpression. histogram shows the log2 (fold changes) of the reporter 
activities of different signaling pathways. the data are presented as the mean ± standard deviation (sd) of three independent experi-
ments. *P < 0.001.
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significantly activated upon miR-124 overexpression (Fig-
ure 1D, >2 fold change, P < 0.001). MiR-124 showed the 
strongest inhibitory effect on the activity of Stat3 signal-
ing pathway (Figure 1D).
stat3 was a direct target of mir-124 in her2-positive 
breast cancer cells
We identified Stat3 as a putative direct target of miR-124 
(Figure 2A). We then performed dual-luciferase report-
er assays to determine whether miR-124 could regulate 
Stat3 expression by directly targeting its 3’-UTR. A mu-
tant construct with a disrupted miR-124 binding site was 
used as a control (Figure 2A). Compared with control, 
miR-124 overexpression in SKBR3 cells inhibited the tran-
scriptional activity of luciferase reporter containing the 
Stat3 3’UTR, but had no effect on the activity of the mu-
tant lacking the miR-29b binding site (Figure 2B). In line 
with this, miR-124 overexpression in SKBR3 cells potent-
ly reduced the expression of endogenous Stat3 protein 
(Figure 2C). Together, these results suggested that Stat3 
was a direct target of miR-124 in HER2-positive breast 
cancer cells.
Figure 2. signal transducer and activator of transcription 
3 (stat3) was a direct target of microrna-124 (mir-124). (A) 
the potential duplexes formed between mir-124 and stat3 
3’-untranslated region region. the sequence of the mutant 
vector lacking the mirna biding site is also shown. (B) sKbr3 
were transiently transfected with the indicated constructs. 
dual luciferase activity was measured 48 h post transfection. 
(C) Western blotting analysis of stat3 expression in sKbr3 fol-
lowing transfection with mir-124 duplex or scramble control. 
the data are presented as the mean ± standard deviation (sd) 
of three independent experiments. *P < 0.001.
Figure 3. Microrna-124 (mir-124) overexpression enhances sensitivity to irradiation. (A) Western blotting for cleaved-poly (adP-
ribose) polymerase (ParP), signal transducer and activator of transcription 3 (stat3), and p-stat3 in sKbr3 cells transfected with mir-
124 or control and treated with irradiation or not treated with irradiation. (B) Flow cytometry analysis of cell death in cells transfect-
ed with scramble or mir-124 and treated with irradiation. Cells were stained with annexin V and propidium iodide. (C) Percentage of 
cell death (b). data are shown as the mean ± standard deviation (sd) of three independent experiments **P < 0.001).
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overexpression of mir-124 enhances response to 
irradiation in her2-positive breast cancer
To test whether miR-124 overexpression enhances re-
sponse to irradiation in HER2-positive breast cancer, SKBR3 
cells were transfected with miR-124 or scramble duplex 
and then treated with 10 Gy irradiation, a dose report-
ed previously (15). As expected, miR-124 overexpression 
largely reduced protein expression of Stat3 and signifi-
cantly abolished Stat3 phosphorylation in SKBR3 cells (Fig-
ure 3A, P < 0.001). It also significantly enhanced the level 
of cleaved poly (ADP-ribose) polymerase (PARP) protein 
upon irradiation, suggesting an increased cell death index 
in these cells (Figure 3A, P < 0.001). In line with these re-
sults, flow cytometry analysis revealed that forced miR-124 
expression dramatically enhanced cell death upon irradia-
tion in SKBR3 cells (Figure 3B and C). In contrast, without 
irradiation miR-124 only slightly induced apoptosis.
stat3 and mir-124 mediates radiotherapy resistance in 
her2-positive breast cancer patients
To further validate the effects of Stat3 on radiotherapy re-
sponse in HER2-positive breast cancer cells, SKBR3 cells 
were treated with Stat3 specific inhibitor, S3I-201, before 
irradiation treatment. Treatment with S3I-201 abolished 
Stat3 phosphorylation and significantly increased radia-
tion-induced cell death (Figure 4A, B), supporting the fact 
that Stat3 is important in mediating radiotherapy resistance 
in HER2-positive SKBR3 breast cancer cells. To further inves-
tigate the physiological relevance of miR-124/Stat3 regula-
tion in radiotherapy resistance, we used qPCR to measure 
the expression of Stat3 and miR-124 in 10 relapsed (non-
responder) and 10 recurrence-free HER2-positive breast 
cancer patients after radiotherapy. As expected, Stat3 ex-
pression was significantly higher in non-responders than 
in responders (P = 0.032, Mann-Whitney U test), while miR-
124 expression was significantly lower in non-responders 
than in responders (P = 0.002, Mann-Whitney U test).
disCussion
In the current study, we showed that miR-124 was down-
regulated in breast cancer, particularly in HER2-postive 
breast cancer. These results support the function of miR-
124 as a tumor suppressor in breast cancer and suggest a 
special regulatory role of miR-124 in HER2-positive breast 
cancer subtypes. Forced miR-124 expression in HER-2 posi-
tive breast cancer cell line SKBR3 resulted in down-reg-
ulation of Stat3 expression, inhibition of Stat3 signaling 
pathway, and enhanced sensitivity to irradiation. Together, 
these in vitro and in vivo results suggest that miR-124/Stat3 
regulation is a key factor in radiotherapy response of HER2-
positive breast cancers. As Stat3 is a key upstream regula-
tor of HER2 expression (16,17), down-regulation of miR-124 
might be a driver event that causes up-regulation of Stat3 
and, subsequently, cells lacking miR-124 are more likely to 
form HER2-positive tumors with a higher resistance to ra-
diotherapy (18,19). This regulatory loop might explain the 
preferential down-regulation of miR-124 in HER2-positive 
breast cancer cells. We thus believe that the miR-124 could 
be a promising new drug target for adjuvant radiotherapy 
in HER2-positive breast cancers.
Figure 4. Microrna-124 (mir-124) expression and signal transducer 
and activator of transcription 3 (stat3) is linked to radiotherapy resis-
tance in vivo. (A) Western blotting for cleaved- poly (adP-ribose) poly-
merase (ParP), stat3, and p-stat3 in sKbr3 cells treated with dimethyl 
sulfoxide (dMso) or s3i-201 and then irradiated. (B) Percentage of cell 
death determined by flow cytometry (C) relative expression of stat3 
expression in recurrence-free (responder; n = 10) and relapsed (nonre-
sponder; n = 10) human epidermal growth factor receptor 2 (her-2)-pos-
itive breast cancer tissues determined by quantitative polymerase chain 
reaction. Mean expression in responders was normalized to 1. data are 
presented as box-and-whisker plots. (D) relative mir-124 expression in 
recurrence-free (responder; n = 10) and relapsed (nonresponder; n = 10) 
her2-positive breast cancer tissues determined by qPCr. interquartile 
ranges are presented as box-and-whisker plots. *P < 0.05.
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It is well established that Stat3 is abnormally activated in 
diverse tumors types (20-22). Triggered by upstream regu-
lators with intrinsic kinase activities such as Janus kinases 
and epidermal growth factor receptor, Stat3 is activated 
by tyrosine/serine phosphorylation and relocated to the 
nucleus, binding to the promoters of their target genes 
to regulate transcription (20,21). A large variety of targets 
with different functions are tightly regulated by Stat3 and 
therefore make it a central linking point for a multitude of 
signaling cascades. For example, genes involved in apop-
tosis (Bcl-2, Bcl-Xl, and Survivin), cell cycle progression (Cy-
clin D1), proliferation (c-Myc and Mcl-1), and epithelial–
mesenchymal transition (TWIST, MMP-9, and MMP-7) are all 
tightly regulated by Stat3 (15,16,22). Therefore, Stat3 has a 
crucial role in the pathogenesis and radiation resistance of 
breast cancer.
Consistently, previous studies have reported that miR-124 
functions as an important tumor suppressor in various can-
cers by targeting a variety of different proteins. For exam-
ple, it has been shown that miR-124 could directly target 
androgen receptor, enhancer of zeste homologue 2, and 
proto-oncogene tyrosine-protein kinase, which all contrib-
ute to prostate cancer progression and treatment resist-
ance. MiR-124 overexpression inhibited the proliferation of 
prostate cancer cells in vitro and sensitized them to inhib-
itors of androgen receptor signaling (13). Moreover, miR-
NA-124 might inhibit glioma cell migration and invasion 
by targeting ROCK1 gene and impairing actin cytoskeleton 
rearrangements and reducing cell surface ruffle (14). No-
tably, the function of a same miRNA might vary in differ-
ent cellular contexts, resulting in cancer subtype-specific 
regulation and response. In the current study, using a Cig-
nal Signal Transduction Reporter Array, we systematically 
scanned the signaling activity changes of 50 major path-
ways upon miR-124 overexpression in HER2-positive cells. 
In addition to Stat3 signaling, we also found robust down-
regulation of mothers against decapentaplegic homo-
logue (SMAD) signaling. Transforming growth factor-β/
SMAD signaling plays a critical role in the regulation of 
cell growth, differentiation, and development (23). Liver X 
receptors signaling, which is a nuclear receptor signaling 
pathway playing a critical role in tumor metabolism and 
inflammatory responses (24), was also significantly down-
regulated upon miR-124 overexpression.
There are several limitations of the current study. First, the 
sample size was small, and further large-scale clinic stud-
ies are required to confirm our findings. Second, we only 
focused on HER-2 positive breast cancer, so further stud-
ies are required to validate the association between miR-
124 expression, HER2 status, and radioresistance in differ-
ent cancer subtypes. Interestingly, Arabkheradmand et 
al (11) reported an association between miR-124 down-
regulation and advanced clinical stage and the presence 
of lymph node metastasis in Iranian patients with breast 
cancer, however, they found no association between mi-
croRNA expression and HER2 status. There are several ex-
planations for the difference between our study and the 
study by Arabkheradmand et al: 1) The complex relation 
between miRNA expression and clinic clinicopathologi-
cal characteristics of the patients might be different in 
the Iranian and Chinese Han populations. 2) The number 
of patients included in both studies was relatively small 
so the results might be affected by bias in patient selec-
tion and tumor heterogeneity. Further large-scale studies 
are required to validate the association between miR-124 
expression, HER2 status, and radioresistance in different 
populations.
In conclusion, these results suggest that miR-124 is a bi-
omarker for HER-2 positive breast cancer and a putative 
novel therapeutic target that can be used to overcome ra-
diotherapy resistance.
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